For the first time, we now have a randomized trial comparing active monitoring, surgery, and radiation therapy for the management of localized prostate cancer.
For the first time, we now have a randomized trial comparing active monitoring, surgery, and radiation therapy for the management of localized prostate cancer. In a recent BJU International article, experts note that the investigators are to be congratulated on their highly anticipated landmark study, the Prostate testing for cancer and Treatment (ProtecT) trial; however, they point to several limitations in the recruitment of patients for the study and differences in the active monitoring protocol in the study compared with contemporary practice.
Considerable advances in treatment methods after the trial may also limit the results’ relevance to current care.
“The utilization of observational data continues to be important in current times,” the authors wrote.
Additional Information:
Study: http://onlinelibrary.wiley.com/doi/10.1111/bju.13734/abstract
About Journal
BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.
Penny Smith-
+44 (0)1243 770171
sciencenewsroom@wiley.com